InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the complete record of transactions filed by Kirchgraber Paul R, Chairman & CEO. Director active across 1 companies, notably Laboratory CORP of America Holdings. Aggregated, 10 filings have been logged. Total volume traded: €1.1m. The latest transaction was filed on 27 March 2022 — Attribution. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations10 total
03,707 shares0
Common Stock
SEC:0001127602-22-010503:0·
317 shares
Common Stock
SEC:0001127602-22-005027:0·
560 shares
Common Stock
SEC:0001127602-22-003649·
560 shares
Common Stock
SEC:0001127602-22-003649:0·
443 shares
Common Stock
SEC:0001127602-22-003279·
443 shares
Common Stock
SEC:0001127602-22-003279:0·
2,007 shares
Common Stock
SEC:0001127602-21-028237·
2,007 shares
Common Stock
SEC:0001127602-21-028237:0·
€572,8732,500 shares@ €229.14930.0028% mcap100.0% of flow
Common Stock
SEC:0001127602-21-015959·
€572,8732,500 shares@ €229.14930.0028% mcap50.0% of flow
Common Stock
SEC:0001127602-21-015959:0·
10 of 10 declarations
About Kirchgraber Paul R
Paul R. Kirchgraber is the Chief Executive Officer of Covance Drug Development at Laboratory Corp of America Holdings. He leads operations with a focus on innovation and service improvement. Kirchgraber is recognized for his leadership in the life sciences sector.
